Lichen planopilaris is an inflammatory disorder that specifically attacks hair follicles, leading to patchy scarring and permanent hair loss on the scalp. The condition progresses slowly and, without early treatment, can result in irreversible damage where hair cannot regrow. While the exact cause remains unclear, experts believe it involves the immune system mistakenly targeting hair follicles, making it critical to understand available treatment options that can slow progression and manage symptoms.

Understanding Treatment Goals for Lichen Planopilaris

When lichen planopilaris affects the scalp, the primary goal of treatment is not to restore hair that has already been lost through scarring. Instead, treatment focuses on slowing down or stopping the progression of hair loss, controlling uncomfortable symptoms such as itching and burning, and reducing the inflammation that destroys hair follicles. Because the scarring that occurs is permanent, early intervention becomes absolutely critical—the sooner treatment begins, the more hair can potentially be preserved.^[1]

Treatment approaches must be tailored to each individual’s situation. Factors such as the extent of hair loss, the severity of symptoms, how rapidly the condition is progressing, and the patient’s overall health all influence which therapies doctors recommend. Some patients may experience periods where the disease is very active, followed by times when it seems to settle down. This unpredictable nature means that treatment plans often need adjustment over time.^[2]

Medical societies and dermatology experts have established standard treatment protocols based on clinical experience and research, but there is no single approach that works for everyone. Additionally, researchers continue to explore new therapies through clinical trials, offering hope for patients who do not respond well to conventional treatments. The journey with lichen planopilaris requires patience, regular monitoring, and close collaboration with dermatology specialists who can guide treatment decisions.^[3]

Standard Treatment Approaches

The foundation of lichen planopilaris treatment rests on medications that reduce inflammation, since this is fundamentally an inflammatory disorder. Corticosteroids—medications that help control inflammation—represent the first-line therapy recommended by dermatology guidelines. These can be applied in several ways depending on the extent and severity of the condition.^[1]

High-potency topical corticosteroids in the form of lotions, gels, foams, or mousses are often prescribed for application directly to affected areas of the scalp. The scalp skin is thicker than facial skin and can generally tolerate stronger steroid preparations without as much risk of side effects. These topical treatments work by reducing inflammation around hair follicles and can help relieve itching and discomfort. However, prolonged use carries some risk of skin thinning (atrophy), so doctors monitor patients carefully during treatment.^[7]

For more localized patches of disease, doctors may recommend intralesional steroid injections. During this procedure, small amounts of corticosteroid medication are injected directly into affected areas of the scalp. While this can be more effective for small patches, the procedure can be uncomfortable or painful, and there is a higher risk of side effects such as scalp atrophy. Some experts caution that extensive use of intralesional steroids might also compromise the success of future hair transplantation procedures if patients later consider that option.^[9]

Another class of topical medications used in lichen planopilaris treatment includes calcineurin inhibitors, specifically tacrolimus and pimecrolimus. These medications also reduce inflammation but work through a different mechanism than corticosteroids. An important advantage is that they carry less risk of causing skin atrophy, making them suitable for longer-term use. Doctors often recommend these when corticosteroids are not well-tolerated or when patients need ongoing maintenance therapy.^[9]

Antimalarial drugs, particularly hydroxychloroquine, represent an important systemic treatment option. While originally developed to treat malaria, these medications also help manage certain inflammatory skin conditions, including lichen planopilaris. A recent analysis from a German tertiary center examined 110 patients with lichen planopilaris and frontal fibrosing alopecia treated with hydroxychloroquine over a 12-month period. The study evaluated treatment response, disease progression-free survival, and safety profiles, demonstrating that hydroxychloroquine serves as a valuable systemic agent for managing this condition.^[14]

Antibiotics, particularly doxycycline, are prescribed not primarily for their antibacterial effects but because they also possess anti-inflammatory properties. These medications can help reduce inflammation around hair follicles and may contribute to slowing disease progression. Treatment courses typically last several weeks to months.^[1]

Retinoids—medications derived from vitamin A—help regulate skin cell growth and can be used to treat lichen planopilaris. These may be applied topically as creams or taken orally as pills. Retinoids work by normalizing the turnover of skin cells and reducing inflammation, though they require careful monitoring due to potential side effects, especially when taken systemically.^[1]

For patients with rapidly progressive disease, short courses of oral corticosteroids such as prednisolone may be necessary to quickly bring inflammation under control. Similarly, cyclosporine—a powerful immunosuppressant medication—can be used in severe cases. However, these stronger systemic medications are typically reserved for acute situations and are not intended for long-term use due to their side effect profiles. The goal is often to stabilize the disease with these medications and then transition to safer maintenance therapies.^[9]

Additional systemic treatment options include mycophenolate mofetil, methotrexate, thalidomide, and 5-alpha reductase inhibitors (medications that block certain hormones). Pioglitazone, a medication originally developed for diabetes, has shown promise in achieving remission for a subset of patients with lichen planopilaris at doses of 15 to 45 mg daily. However, patients considering this option should be informed about its labeled indication, the mixed evidence regarding effectiveness for this condition, and a boxed warning about potential bladder cancer risk with prolonged use.^[9]

Non-pharmacologic interventions also play a role in comprehensive management. Low-level laser therapy uses special light waves to treat scalp inflammation. Some studies have suggested potential benefits from excimer laser treatments. While these approaches do not directly control the underlying inflammatory process, they may provide symptomatic relief for some patients.^[1]

Although minoxidil—available in topical and oral formulations—does not address the autoimmune inflammation causing lichen planopilaris, it can be used to maximize hair regrowth in patients who also experience inherited pattern alopecia, which affects almost half the population. This dual approach targets both the inflammatory hair loss and any concurrent genetic hair thinning.^[9]

Treatment duration varies considerably depending on individual response and disease activity. Some patients may need to continue medications for months or years to keep the condition under control. Regular follow-up appointments are essential so doctors can monitor progress through clinical examination and sometimes through photographs or measurements of affected areas. Blood tests may be required for patients on certain systemic medications to check for potential side effects.^[7]

Side effects depend on which medications are used. Topical corticosteroids can cause skin thinning, stretch marks, or changes in skin color if used excessively. Oral corticosteroids, when needed for short periods, may cause weight gain, mood changes, elevated blood sugar, or increased infection risk. Hydroxychloroquine requires periodic eye examinations because long-term use can rarely affect vision. Retinoids may cause dryness, sun sensitivity, and birth defects if used during pregnancy. Each medication carries its own risk-benefit profile that doctors discuss with patients before starting treatment.^[7]

Innovative Treatments Being Tested in Clinical Trials

Beyond standard therapies, researchers are investigating promising new treatment approaches for lichen planopilaris through clinical trials. These studies aim to find more effective options, especially for patients whose condition does not respond adequately to conventional treatments.

One of the most exciting developments involves JAK inhibitors—medications that block specific signaling pathways used by the immune system. Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has demonstrated effectiveness against several immune-mediated skin conditions, including atopic dermatitis, alopecia areata, and vitiligo. Its immune-modulating activity works by inhibiting the JAK/STAT signaling pathway, which plays a crucial role in transmitting inflammatory signals within cells.^[9]

In lichen planopilaris, research suggests that interferons—proteins involved in immune responses—facilitate the recruitment of lymphocytes (immune cells) to hair follicles and contribute to the loss of immune privilege that normally protects the hair bulge area. By affecting the JAK/STAT pathway, tofacitinib may reduce this interferon-mediated inflammation, potentially improving symptoms and preventing further destruction of hair follicles.^[9]

A retrospective study investigated the therapeutic potential of both topical and oral formulations of tofacitinib in treating refractory lichen planopilaris—cases that had not responded to other therapies. This represents one of the early studies exploring tofacitinib’s use specifically for this condition. The study included nine patients who had failed previous treatments; three used topical tofacitinib, five used the oral form, and one tried both formulations. A favorable initial response was achieved in all but one patient, and that individual later improved when switched from topical to systemic therapy.^[9]

Although the patient numbers were small, there appeared to be a trend toward better clinical response in those receiving systemic treatment compared to topical application. The time required to see favorable responses ranged from one to seven months, with five patients showing improvement within the first three months and eight patients demonstrating progress within five months of starting treatment. These preliminary results suggest that JAK inhibitors may offer a valuable option for patients with difficult-to-treat lichen planopilaris.^[9]

Recent studies have also explored the potential of low-dose oral naltrexone, a medication that modulates immune function. While the mechanism is not fully understood, some patients have reported improvements in symptoms. However, as with other experimental approaches, results have been variable and more research is needed to establish effectiveness.^[9]

Platelet-rich plasma (PRP) injections represent another investigational approach being studied for lichen planopilaris. This treatment involves drawing a small amount of the patient’s blood, processing it to concentrate the platelets (which contain growth factors), and then injecting this preparation into affected areas of the scalp. The theory is that growth factors released by platelets might promote healing and reduce inflammation. Early studies have suggested potential benefits, though evidence remains preliminary and not all patients respond.^[9]

The mechanism of action for these innovative therapies generally involves modulating specific aspects of the immune response. Rather than broadly suppressing the immune system, newer treatments aim to target particular pathways involved in the inflammatory process that damages hair follicles. This targeted approach may potentially offer better effectiveness with fewer side effects compared to traditional immunosuppressants.

Clinical trials for lichen planopilaris treatments progress through standard phases. Phase I trials focus primarily on safety—determining whether a treatment causes unacceptable side effects and establishing appropriate dosing. Phase II trials begin to evaluate effectiveness, measuring whether the treatment actually improves clinical parameters such as reduction in scalp inflammation, decreased symptom severity, or slowing of hair loss progression. Phase III trials compare the new treatment directly against standard therapies to determine if it offers advantages in effectiveness or safety.^[2]

Trial locations vary—some research is conducted at specialized dermatology centers in the United States, while others take place in Europe or other regions. Patient eligibility for clinical trials typically depends on factors such as the severity and type of lichen planopilaris, previous treatments tried, overall health status, and willingness to participate in research protocols that may include additional testing and monitoring visits.

Most common treatment methods

• Corticosteroid therapy
  • High-potency topical corticosteroids applied as lotions, gels, foams, or mousses directly to the scalp to reduce inflammation and relieve itching
  • Intralesional steroid injections delivered directly into affected scalp patches for more localized disease control
  • Short-term oral corticosteroids such as prednisolone for rapidly progressive disease to quickly control acute inflammation
• Topical immunomodulators
  • Calcineurin inhibitors including tacrolimus and pimecrolimus that reduce inflammation without the risk of skin atrophy associated with corticosteroids
  • Suitable for longer-term maintenance therapy when corticosteroids are not well-tolerated
• Systemic antimalarial therapy
  • Hydroxychloroquine used to manage inflammatory processes in lichen planopilaris
  • Requires periodic eye examinations during long-term treatment due to rare vision-related side effects
• Antibiotic therapy
  • Doxycycline prescribed for its anti-inflammatory properties rather than antibacterial effects
  • Treatment courses typically lasting several weeks to months
• Retinoid therapy
  • Medications derived from vitamin A applied topically as creams or taken orally as pills
  • Work by regulating skin cell growth and reducing inflammation
• JAK inhibitors (investigational)
  • Tofacitinib available in topical and oral formulations blocks the JAK/STAT signaling pathway involved in inflammation
  • Studied for refractory cases that do not respond to standard treatments
  • Response time ranging from one to seven months in preliminary studies
• Additional systemic immunosuppressants
  • Cyclosporine for severe cases requiring powerful immunosuppression
  • Mycophenolate mofetil, methotrexate, and thalidomide for difficult-to-control disease
  • Pioglitazone at doses of 15 to 45 mg daily shown to achieve remission in some patients
• Light-based therapies
  • Low-level laser therapy using special light waves to treat scalp inflammation
  • Excimer laser treatments explored in some studies for potential symptomatic relief
• Platelet-rich plasma therapy (investigational)
  • Injections of concentrated platelets containing growth factors into affected scalp areas
  • Aimed at promoting healing and reducing inflammation with variable patient responses
• Supportive hair treatments
  • Topical and oral minoxidil to maximize hair regrowth in patients with concurrent inherited pattern alopecia
  • Does not control underlying inflammatory process but addresses additional hair thinning